STING1 and neoplasm: Notably, when the STING protein is activated in tumor cells, it triggers the production of IFN-β, which reverses the downregulation of MHC-I expression, leading to the escape of tumor cells from immune recognition by cytotoxic T-lymphocytes (CTLs) [45].